Wells Fargo
NMRA icon

Wells Fargo’s Neumora Therapeutics NMRA Stock Holding History

Wells Fargo’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$168K Buy
98,607
+93,107
+1,693% +$177K ﹤0.01% 5301
2026
Q1 		$10.7K Sell
5,500
-4,500
-45% -$11.7K ﹤0.01% 5949
2025
Q4 		$17.9K Buy
10,000
+5,000
+100% +$10.9K ﹤0.01% 5818
2025
Q3 		$9.1K Sell
5,000
-1,826
-27% -$2.95K ﹤0.01% 5966
2025
Q2 		$5.01K Sell
6,826
-38,894
-85% -$29.5K ﹤0.01% 6088
2025
Q1 		$45.7K Sell
45,720
-24,933
-35% -$42.7K ﹤0.01% 5432
2024
Q4 		$749K Buy
70,653
+13,196
+23% +$158K ﹤0.01% 3905
2024
Q3 		$759K Sell
57,457
-1,023
-2% -$11.9K ﹤0.01% 3723
2024
Q2 		$575K Buy
58,480
+23,537
+67% +$244K ﹤0.01% 3822
2024
Q1 		$480K Buy
34,943
+7,588
+28% +$123K ﹤0.01% 3918
2023
Q4 		$466K Buy
+27,355
New +$336K ﹤0.01% 3919

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Wells Fargo's NMRA Position: Q2 2026 in Review

Wells Fargo increased its Neumora Therapeutics (NMRA) stake by 1,693% in Q2 2026, buying an estimated $177K and bringing the position to 98,607 shares worth $168K. The position accounts for ﹤0.01% of the portfolio, ranked #5301.

Wells Fargo first reported a position in NMRA in Q4 2023 and has held it in 11 quarters since. The position peaked at $759K in Q3 2024. 113 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

  • Wells Fargo held 98,607 shares of Neumora Therapeutics worth $168K as of Q2 2026.
  • Wells Fargo bought 93,107 Neumora Therapeutics shares in Q2 2026, an estimated $177K.
  • Neumora Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #5301 holding.
  • Wells Fargo first reported a position in Neumora Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • Wells Fargo's Neumora Therapeutics position peaked at $759K in Q3 2024.
  • 113 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.